Comparison of 5‐aminolaevulinic acid and porphyrin photosensitization for photodynamic therapy of malignant bronchial stenosis: A clinical pilot study

Maier, Andrea B.; Tomaselli, Florian; Matzi, Veronika; Woltsche, Michael; Anegg, Udo; Fell, B.; Rehak, Peter; Pintér, H; Smolle‐Jüttner, Freyja Maria

doi:10.1002/lsm.10009

Cited by 23 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tetra (m-hydroxyphenyl) chlorine has been used by some [30] but no conclusion can be drawn from published literature because of the lack of precise information related specifically to its use in lung cancer. Systemic ALA has only been tried in one small series [25]. At the present time the number of lung cancer patients in whom drugs other than Photofrin have been used is too small for conclusions to be drawn regarding their safety or efficacy in endoscopic bronchial cancer situations.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?

Moghissi¹,

Dixon²

2003

Eur Respir J

View full text Add to dashboard Cite

This study addresses whether photodynamic therapy (PDT) is a valid therapeutic option in lung cancer treatment.A total of 24 articles were reviewed in two categories: advanced (G1) and early (G2) disease. Details considered included the following: 1) number of patients in each series; 2) staging; 3) methodology; 4) mortality; 5) morbidity; 6) survival; 7) relief of symptoms; and 8) concomitant treatments. G1 (636 patients) had severe endobronchial obstructive cancer and PDT was primarily for symptom relief. G2 (517 patients) had early stage cancer and were treated with PDT for curative intent.There was no procedure-related mortality in either group. G1 had a 5-28% incidence of skin sensitivity. Haemoptysis occurred in two series; one fatal, an incidence of 2.2%. Almost all patients had symptomatic relief. Patients with lower disease stage and better performance status had improved survival rates. G2 had a 8-28% incidence of sunburn. Three patients in one series (38 patients) had haemoptysis. Survival after 5 yrs in complete remission/response patients was 70%.This review suggests that bronchoscopic photodynamic therapy has indications in selected lung cancer patients with early or advanced stage disease. However, in the absence of a formal comparative study, no claim can be made of its superiority over other endobronchial therapies. In the case of lung cancer, PDT refers to the endoscopic treatment of tumour, the location and extent of which is first assessed bronchoscopically. A photosensitiser is then administered to the patient by i.v. injection. This is followed, after an interval, by illumination of the presensitised tumour by an appropriate laser light, which is delivered to the target tissue via an optical fibre through the bronchoscope. The light and chemical interaction leads to necrosis of the tumour.Using the above principle, after experimental and preclinical work, KATO [2] used PDT for the first time in 1980 to treat a patient with early lung cancer who refused surgical intervention. Following bronchoscopic PDT, the patient had complete remission (CR) for 4 yrs and died later from a noncancer related cause.The last 20 yrs has seen many publications on PDT for lung cancer showing its therapeutic usefulness in different stages of the disease. In spite of this, in Europe at least, PDT has not become a mainstream lung cancer treatment option even though there is desperate need for newer therapeutic methods other than the traditional trio of surgery, radiotherapy and chemotherapy. It is generally acknowledged that surgical and oncological advances over the past 40-50 yrs have had little impact on either early detection, resection rate or on survival of lung cancer patients.With this background the authors undertook a review of the literature to evaluate the current state of PDT and to discuss the place of PDT for lung cancer treatment within the overall therapeutic options. Material and methodsA literature search was made through Medline (PubMed) for listed articles on PDT in broncho-pulmonary ...

show abstract

Section: Discussionmentioning

confidence: 99%

“…Later publications show that the standard dose became 2 mg?kg -1 ?bw -1 . A small number of patients in one series used 5-aminolevulinic acid (ALA) [25].…”

Section: Photosensitisermentioning

confidence: 99%

Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?

Moghissi¹,

Dixon²

2003

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…In the trial comparing ALA-PDT with Photosan, no major complications relating to photosensitisation were observed. 127 This same trial found only minor complications (fever and mild chest pain) in both groups, none of which required specific treatment. Diaz-Jimenez et al 122 found bronchitis to be the most common AE (4/14 in the PDT group compared to one in the Nd:Yag group).…”

Section: Results Of Safetymentioning

confidence: 89%

“…[121][122][123][124][125][126][127] Five trials were reported in full papers [122][123][124]126,127 and two as abstracts only. 121,125 All trials had a palliative intent in relation to non-small cell lung cancer.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

124

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Bronchoscopy

Freitag¹,

Darwiche²,

Hüttenberger³

2012

Handbook of Biophotonics

View full text Add to dashboard Cite

The sections in this article are Diagnostics Cancer Detection Filter‐Based Techniques for Tumor Detection Fluorescence Techniques, Drug Induced Fluorescence Fluorescence Techniques, Auto‐Fluorescence Commercially Available Systems Remaining Problems Therapy Lasers in Bronchology Thermal Laser Applications Photodynamic Therapy New Techniques: Fluorescence Microimaging, Optical Coherence Tomography

show abstract

Comparison of 5‐aminolaevulinic acid and porphyrin photosensitization for photodynamic therapy of malignant bronchial stenosis: A clinical pilot study

Abstract: Despite the limitations of a non-randomized study, photosensitization with Photosan seems to be more effective in PDT of malignant tracheo-bronchial stenosis compared to ALA.

Cited by 23 publications

References 21 publications

Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?

Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Bronchoscopy

Contact Info

Product

Resources

About